Allogeneic genetically-modified NK cell therapy

Class

Allogeneic genetically-modified NK cell therapy

Pathway

Innate NK cell-mediated cytotoxicity

Natural killer (NK) cells are innate immune lymphocytes that recognize and kill abnormal cells, such as tumor or virus-infected cells, without requiring prior antigen exposure. Their activity is governed by a balance of activating and inhibitory receptor signals; loss of normal 'self' markers on a diseased cell, or upregulation of stress ligands, tips this balance toward killing via release of cytotoxic granules and pro-inflammatory cytokines. This mechanism entry describes an allogeneic, genetically-modified NK cell therapy: NK cells sourced from a healthy donor (rather than the patient) and engineered—for example, with a chimeric antigen receptor, added cytokine support, or edits to reduce rejection—to improve tumor targeting and manufacturing scalability. The allogeneic approach is attractive because NK cells, unlike donor T cells, generally do not cause graft-versus-host disease, allowing an 'off-the-shelf' product usable across multiple recipients rather than one manufactured individually for each patient. Genetic engineering aims to sharpen tumor recognition, extend the cells' functional lifespan after infusion, and reduce the likelihood that the host immune system rapidly eliminates the transplanted cells. This class of therapy is being explored broadly across hematologic malignancies and solid tumors, where redirecting or reinforcing innate immune killing offers a complementary approach to antibody- and T-cell-based strategies.